(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
9 October 2008 (09.10.2008)

PCT

(10) International Publication Number
WO 2008/119741 A3

(51) International Patent Classification:
C07D 403/04 (2006.01) *A61P 35/00* (2006.01)
A61K 31/4164 (2006.01)

(21) International Application Number:
PCT/EP2008/053667

(22) International Filing Date: 27 March 2008 (27.03.2008)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
07105269.0 29 March 2007 (29.03.2007) EP

(71) Applicant *(for all designated States except US)*: **NOVARTIS AG** [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **BOETTCHER, Andreas** [DE/CH]; Röttelerstr. 15, CH-4058 Basel (CH). **BUSCHMANN, Nicole** [DE/CH]; Horburgstrasse 19, CH-4057 Basel (CH). **FURET, Pascal** [FR/FR]; 19, rue de la Forêt, F-68800 Thann (FR). **GROELL, Jean-Marc** [FR/FR]; Rue de Muespach 4a, F-68640 Steinsoultz (FR). **KALLEN, Jörg** [CH/CH]; Kaltbrunnenstrasse 41, CH-4054 Basel (CH). **HERGOVICH LISZTWAN, Joanna** [CA/FR]; 11b rue de Delle, F-68640 Muespach Le Haut (FR). **MASUYA, Keiichi** [JP/CH]; Gemeindeholzweg 30, CH-4103 Bottmingen (CH). **MAYR, Lorenz** [DE/DE]; Fritz-Schülin-Weg 16, 79589 Binzen (DE). **VAUPEL, Andrea** [DE/CH]; Rütiring 23, CH-4125 Riehen (CH).

(74) Agent: **DYER, James**; Novartis Pharma Ag, Patent Department, CH-4002 Basel (CH).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.


(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declaration under Rule 4.17:
— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:
— *with international search report*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

(88) Date of publication of the international search report:
4 December 2008

(54) Title: 3-IMIDAZOLYL-INDOLES FOR THE TREATMENT OF PROLIFERATIVE DISEASES



(I)

(57) Abstract: The invention relates to 3-heterocyclyl indolyl compounds capable of inhibiting the interaction between p53, or variants thereof, and MDM2 and/or MDM4, or variants thereof, respectively, said compounds having the formula (I) wherein R^1, R^2, R^3, R^4, R^A, Y and Y are as defined in the specification. Due to their activity, the compounds are useful in the treatment of various disorders and diseases mediated by the activity of MDM2 and/or MDM4, or variants thereof, such as inflammatory or proliferative diseases or in the protection of cells.

WO 2008/119741 A3